GENB at a glance
Generate Biomedicines Inc (GENB, SEC CIK 2100782) filed a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 26, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Generate Biomedicines Inc (GENB) shares worth $258.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ARNOLD FRANCES on September 1, 2026 of 1,000 shares at $16.00 per share.
- In the last 90 days, GENB insiders reported 0 open-market purchases ($0) and 1 open-market sale ($16K) on Form 4, a net sale of $16K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$16K
- 13F holders
- 21 funds
- $258.7M · +7 vs prior quarter
- Latest 10-Q
- Aug 6, 2026
- Quarterly report
SignalX for GENB
Don't miss the next GENB filing
- Alerts as it files. A push when GENB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GENB, by share count.
- Ask anything. An AI agent that reads every GENB filing and answers with sources.
GENB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| ARNOLD FRANCES | Sell | Sep 1, 2026 | 1,000 | $16.00 |
| Nally Michael | Buy | Mar 4, 2026 | 20,000 | $12.00 |
| AFEYAN NOUBAR | Buy | Mar 2, 2026 | 1,562,500 | $16.00 |
| AFEYAN NOUBAR | C | Mar 2, 2026 | 13,702,224 | - |
| AFEYAN NOUBAR | C | Mar 2, 2026 | 987,491 | - |
| AFEYAN NOUBAR | C | Mar 2, 2026 | 2,777,752 | - |
| AFEYAN NOUBAR | Buy | Mar 2, 2026 | 1,562,500 | $16.00 |
| AFEYAN NOUBAR | C | Mar 2, 2026 | 2,777,752 | - |
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate GENB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $258.7M |
| Q1 2026 | 14 | $145.1M |
- FMR LLC (Fidelity)+1.00M (+24%)
- Vanguard Capital Management LLC+1.00M (+763%)
- ARK Investment Management+786.2K (+158%)
- T. Rowe Price Group+47.0K (+2%)
- Morgan Stanley+40.7K (+12%)
- JPMorgan Chase & Co−1.54M (-52%)
- Millennium Management−355.0K (-94%)
- Goldman Sachs Group−159.5K (-93%)
- BlackRock+1.66M
- State Street Corp+526.6K
- Northern Trust+197.5K
- Vanguard Portfolio Management LLC+167.3K
- BNY Mellon+57.3K
- D.E. Shaw & Co−95.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 35 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GENB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 26, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | - | - |
| 10-Q | May 7, 2026 | Mar 31, 2026 | - | |
| 8-K | May 7, 2026 | - | - | |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 4 | Mar 2, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GENB SEC filings: frequently asked questions
Are GENB insiders buying or selling?
In the last 90 days, Generate Biomedicines Inc (GENB) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $16,002 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GENB stock?
As of June 30, 2026, the largest Generate Biomedicines Inc (GENB) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($88.1 million), T. Rowe Price Group ($36.4 million), BlackRock ($28.0 million), JPMorgan Chase & Co ($23.8 million), ARK Investment Management ($21.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest GENB SEC filings?
Generate Biomedicines Inc (GENB) filed a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 26, 2026 and a Form 4 insider filing on September 3, 2026.
What is GENB's SEC CIK number?
Generate Biomedicines Inc (GENB)'s SEC Central Index Key (CIK) is 2100782. EDGAR lists every GENB filing under that number.
Ask anything about GENB
The research agent reads GENB's filings, financials, insider trades and 13F holders, then answers with sources.